Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | 5542285 |
| Sektor | Hälsovård |
| Industri | Bioteknik |
OSLO, NORWAY - June 29, 2023: Microbiome DX company Genetic Analysis AS ("GA" or "the Company") announces that the Company has been awarded a patent (2017/06307) by the South African Companies and Intellectual Property Commission (CIPC). The important patent entitled "A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS" covers the Company's unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in the EU and some other countries for this patent.
The subject matter of this family of patents relates to the sophisticated algorithms developed by Genetic Analysis that analyse and characterize gut microbiota in relation to healthy populations. The invention concerns the diagnosis, monitoring and/or characterization of diseases and conditions associated with perturbations in the microbiota of the gastrointestinal tract. More specifically, the invention provides means by which the state of the microbiota may be assessed, and deviations (dysbiosis) from the normal state (normobiosis) may be determined in a manner that is straightforward to perform, reliable and robust.
The patent family claims priority from 27 March 2015 and will be in force until 2036.
CEO Ronny Hermansen comments:
"We are delighted to announce that our patent `A method for determining gastrointestinal tract dysbiosis' has been approved in South Africa. The approval is an important step forward in GA's international expansion and further strengthens our IP portfolio, which already includes six patent families in key markets".
For more information, please contact:
Kari Furu, Head of Business and Product Development
E-mail: kf@genetic-analysis.com